49.95
-2.24 (-4.29%)
| Previous Close | 52.19 |
| Open | 51.09 |
| Volume | 307,689 |
| Avg. Volume (3M) | 698,175 |
| Market Cap | 2,366,239,744 |
| Price / Earnings (TTM) | 12.77 |
| Price / Earnings (Forward) | 11.56 |
| Price / Sales | 2.33 |
| Price / Book | 1.31 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Profit Margin | 18.86% |
| Operating Margin (TTM) | 34.03% |
| Diluted EPS (TTM) | 4.29 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Quarterly Earnings Growth (YOY) | 1.40% |
| Total Debt/Equity (MRQ) | 56.91% |
| Current Ratio (MRQ) | 4.20 |
| Operating Cash Flow (TTM) | 251.52 M |
| Levered Free Cash Flow (TTM) | 188.69 M |
| Return on Assets (TTM) | 6.50% |
| Return on Equity (TTM) | 12.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Prestige Consumer Healthcare In | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.25 |
|
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.23% |
| % Held by Institutions | 108.15% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BYOM JOHN E | 52.00 | - | 2,981 | 155,012 |
| CLARK CELESTE A. | 52.00 | - | 2,981 | 155,012 |
| DARECCA JAMES | 52.00 | - | 2,981 | 155,012 |
| KELLY JOHN F. | 52.00 | - | 2,981 | 155,012 |
| ZIER DAWN M. | 52.00 | - | 2,981 | 155,012 |
| Aggregate Net Quantity | 14,905 | |||
| Aggregate Net Value ($) | 775,060 | |||
| Aggregate Avg. Buy ($) | 52.00 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BYOM JOHN E | Director | 04 Aug 2026 | Acquired (+) | 2,981 | 52.00 | 155,012 |
| CLARK CELESTE A. | Director | 04 Aug 2026 | Acquired (+) | 2,981 | 52.00 | 155,012 |
| DARECCA JAMES | Director | 04 Aug 2026 | Acquired (+) | 2,981 | 52.00 | 155,012 |
| KELLY JOHN F. | Director | 04 Aug 2026 | Acquired (+) | 2,981 | 52.00 | 155,012 |
| ZIER DAWN M. | Director | 04 Aug 2026 | Acquired (+) | 2,981 | 52.00 | 155,012 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |